Evidence map›Paper›PMID 26565618›Full record

ArticleOrganic & biomolecular chemistry2016

Oligomycins as inhibitors of K-Ras plasma membrane localisation.

A A Salim, L Tan, X-C Huang, K-J Cho, E Lacey, J F Hancock, R J Capon

Abstract read
In one paragraph

Article in Organic & biomolecular chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Ras Variant Biology and Contributions to Human Disease.Methods in molecular biology (Clifton, N.J.) · 2021
    Review
  7. Natural products and other inhibitors of FEuropean journal of medicinal chemistry · 2020
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

A A SalimInstitute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia. r.capon@uq.edu.au.
L Tan
X-C Huang
K-J Cho
E Lacey
J F Hancock
R J Capon

Funding

K-Ras plasma membrane interactions: a tractable therapeutic targetR00CA188593 · NCI · WRIGHT STATE UNIVERSITY · PI CHO, KWANGJIN · 2017 to 2019
$747k
K-Ras plasma membrane interactions: a tractable therapeutic targetK99CA188593 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CHO, KWANGJIN · 2014 to 2015
$178k
NCI NIH HHS 1K99-CA188593NCI NIH HHS K99 CA188593NCI NIH HHS R00 CA188593
6 · The paper itself

Abstract

Frequently present in pancreatic, colorectal and non-small cell lung carcinomas, oncogenic mutant K-Ras must be localised to the plasma membrane (PM) to be functional. Inhibitors of K-Ras PM localisation are therefore putative cancer chemotherapeutics. By screening a microbial extract library in a high content cell-based assay we detected the rare oligomycin class of Streptomyces polyketides as inhibitors of K-Ras PM localisation. Cultivation and fractionation of three unique oligomycin producing Streptomyces strains yielded oligomycins A-E (1-5) and 21-hydroxy-oligomycin A (6), together with the new 21-hydroxy-oligomycin C (7) and 40-hydroxy-oligomycin B (8). Structures for 1-8 were assigned by detailed spectroscopic analysis. Cancer cell viability screening confirmed 1-8 were cytotoxic to human colorectal carcinoma cells (IC50 > 3 μM), and were inhibitors of the ABC transporter efflux pump P-glycoprotein (P-gp), with 5 being comparable in potency to the positive control verapamil. Significantly, oligomycins 1-8 proved to be exceptionally potent inhibitors of K-Ras PM localisation (Emax 0.67-0.75 with an IC50 ~ 1.5-14 nM).

Indexed as

AnimalsCell Line, TumorCell MembraneCell ProliferationCell SurvivalColorectal NeoplasmsDogsDose-Response Relationship, DrugHumansMadin Darby Canine Kidney CellsOligomycinsProtein Transportras ProteinsStructure-Activity RelationshipOligomycinsras Proteins

Identifiers

PMID26565618
PMCPMC4689619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.